All In Biotech

NDA 022311 · Genzyme

Mozobil

Plerixafor · Subcutaneous · Hematopoietic Stem Cell Mobilizer

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Dec 15, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

166

8 Phase 3, 14 recruiting

FAERS reports

1,485

1,174 serious, 244 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 19, 2025.

Plerixafor is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma. ( 1 )

Mechanism: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 15, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLetterLabel
1 products under this application
  • MOZOBIL · PLERIXAFOR 24MG/1.2ML (20MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Plerixafor" as an intervention, any sponsor and status, largest first.

All 166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia144
  • off label use127
  • diarrhoea100
  • pyrexia86
  • mucosal inflammation83
  • nausea82
  • thrombocytopenia82
  • death60
  • plasma cell myeloma60
  • pneumonia58
  • neutropenia57
  • vomiting57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200920
201041
201173
2012114
201374
201449
201553
201648
201769
201862
2019107
2020139
2021204
202286
202375
2024127
202594
202650

Recalls

2 FDA enforcement reports for this application.

  • Sep 1, 2016 · Class III · Terminated

    Labeling: Incorrect or Missing Package Insert

  • Aug 4, 2016 · Class III · Terminated

    Labeling: Incorrect or Missing Lot and/or Exp. Date

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Mar 13, 2026

    Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12). A business decision was made to discontinue manufacture of the drug.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Mozobil* (Plerixafor*) · HCPCS J2562

2024 spending

$6.1M

Beneficiaries

1,360

2,068 claims

Per beneficiary

$4,449

2024 ASP limit $118.59 per unit

View as table
YearSpending
2020$17,787,709
2021$18,573,469
2022$22,411,107
2023$23,487,370
2024$6,051,040

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 142 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.